论文部分内容阅读
目的观察环孢菌素A联合化疗治疗难治性急性髓性白血病疗效。方法治疗组70例患者采用粒细胞集落刺激因子+亚砷酸+环孢菌素A化疗前1d应用,阿糖胞苷第1~7d,米托蒽醌第5~7d即MA(7+3)的化疗方案化疗。对照组67例患者采用常规的阿糖胞苷第1~7d,蒽环类化疗药物(米托蒽醌或柔红霉素)第1~3d即MA或DA(3+7)的化疗方案化疗。结果治疗组完全缓解率(Complete remission rate,CR)为71.4%,对照组CR为46.2%,治疗组总缓解率(Total Remission rate,TR)为87.1%,对照组TR为67.1%。治疗组缓解率与对照组相比,CR及TR差异均有统计学意义(P值均<0.01)。结论环孢菌素A+亚砷酸+粒细胞集落刺激因子联合化疗方案MA(7+3)能明显提高复发难治急性髓系白血病完全缓解率,显著降低病死率,经济实用,便于临床应用。
Objective To observe the efficacy of cyclosporin A combined with chemotherapy in refractory acute myeloid leukemia. Methods 70 patients treated with granulocyte colony-stimulating factor + arsenite + cyclosporin A 1 d before chemotherapy, cytarabine 1-7 days, mitoxantrone 5-7 days MA (7 +3) ) Chemotherapy regimen chemotherapy. The control group of 67 patients with conventional cytarabine 1 ~ 7d, anthracycline chemotherapy (mitoxantrone or daunorubicin) 1 ~ 3d MA or DA (3 +7) chemotherapy regimen . Results The complete remission rate (CR) was 71.4% in the treatment group and 46.2% in the control group. The total remission rate (TR) was 87.1% in the treatment group and 67.1% in the control group. The remission rate of treatment group compared with the control group, CR and TR differences were statistically significant (P all <0.01). Conclusion Cyclosporine A + arsenite + granulocyte colony-stimulating factor combined with chemotherapy MA (7 + 3) can significantly improve the complete remission rate of refractory acute myeloid leukemia relapse, significantly reduce mortality, economical and practical, easy to clinical application.